Coherus Oncology (CHRS) Share-based Compensation (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 881.48% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 61.86% YoY), and the FY2025 full-year result was $10.7 million, down 56.5% from the prior year.
• Share-based Compensation grew to $2.4 million in Q1 2026, from $14000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.1 million in Q2 2023 to a low of -$35.3 million in Q4 2022.
• A 5-year average of $410176.5 and a median of $394000.0 in 2024 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 2046.47% in 2022, while the deepest fall reached 422.19% in 2022.
• Tracing CHRS's Share-based Compensation over 5 years: stood at -$35.3 million in 2022, then jumped by 101.03% to $365000.0 in 2023, then plunged by 390.14% to -$1.1 million in 2024, then soared by 101.32% to $14000.0 in 2025, then jumped by 16935.71% to $2.4 million in 2026.
• Business Quant data shows CHRS's Share-based Compensation at $2.4 million in Q1 2026, $14000.0 in Q4 2025, and $19000.0 in Q3 2025.